About IPCA Laboratories Ltd.

Ipca Laboratories Limited is an Indian pharmaceutical company with its head office in Mumbai, Maharashtra, India. Incorporated in 1949 as The Indian Pharmaceutical Combine Association Limited and renamed Ipca Laboratories Limited in 1964, the company manufactures and sells branded and generic formulations, APIs and intermediates to 120+ countries worldwide, including India (44%), and overseas (56%), i.e. Europe, Africa, Americas, Asia, CIS countries and Australasia.

 

The company was named in Asia’s 200 Best Under A Billion list in 2003, 2004, 2005 and 2007, and has been partnering with international clients such as AstraZeneca, GlaxoSmithKline, Merck, Roche and Sanofi Aventis for many years.

 

The company operates in the following segments:

  • Branded formulations, amounting to 47% of total revenues
  • Generic formulations, amounting to 29% of total revenues
  • APIs and Intermediates, amounting to 22% of total revenues
  • Others, amounting to 2% of total revenues

 

In the fiscal year ending 31 March 2015, the company:

  • Had 16 manufacturing facilities in India
  • Had Invested 5.14% of its annual revenues on R&D
  • Had 750+ scientists
  • Was manufacturing:
    • 350+ formulations in the form of oral liquids, tablets, dry powders and capsules
    • 80 APIs
  • Was among the market leaders in 5 therapeutic areas in India, especially in anti-malarials (34% market-share), and rheumatoid arthritis

 

Ipca Laboratories Limited is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).

 

Ipca Laboratories Limited at-a-glance

  • Employees        13,013
  • Turnover (31 March, 2015) ~USD 512 m
  • Markets Served (countries) 120+
  • Manufacturing Facilities 16  
  • Patent Applications Filed 228
  • Exports (countries) 120+
  • Key Markets UK

Australia

New Zealand

South Africa

USA

Canada

Approvals UK-MHRA

TGA-Australia

MCC-South Africa

HPB-Canada

WHO-Geneva

US-FDA

WHO-GMP

INVIMA Colombia

EDQM

Danish Regulatory Authority

PMDA-Japan

GMP

Source: http://www.ipcalabs.com/pdf/finance/annual_report_2014_15.pdf, http://www.ipcalabs.com/pdf/Ipca_corporate_Presentation.pdf

 

Milestones

  • 1949 – Incorporated as The Indian Pharmaceutical Combine Association Limited by group of medical professionals:
    Dr. NK Chaina, Dr. AM Desai, Dr. NS Tibrawala, KM Shroff, SF Kirawal, UH Dalal and KB Mehla.
  • 1966 – Renamed Ipca Laboratories Private Limited
  • 1975 – Management is taken over by Amitabh Bachchan, Ajitabh Bachchan, Jaya Bachchan, MR Chandurkar and PC Godha
  • 1976 – Starts marketing sugarcoated Chloroquine tablets for the first time in India
  • 1988 – Renamed Ipca Laboratories Ltd.
  • 1993
    • Acquires Hoechst India's formulations unit at Kandla
    • Becomes a Public Limited Company
  • 1994
    • Launches maiden public issue of shares
    • Acquires an API manufacturing plant from BDH Pharmaceuticals
      (a subsidiary of E-Merck) at Indore
  • 1995 – Commissions modern formulations plant at Athal (Silvassa)
  • 1996 – Commissions new API R&D Centre at Mumbai
  • 1997
    • Launches Comprehensive Cardiac Care Domestic Marketing Division to promote cardiac care products
    • Receives approval from UK’s MHRA for its Formulations manufacturing unit at Athal, and from MCC South Africa for its Athal, Kandla and Ratlam Formulations manufacturing units
  • 2000 – Receives ISO 9001 certification for Athal Formulations plant
  • 2001
    • Receives Trishul Award from CHEMEXIL for outstanding export performance
    • Acquires National Druggists (Pty) Ltd. (South Africa)
    • Ipca Pharma Nigeria Ltd. is incorporated in Nigeria
  • 2002 – Laboratories Ipca Do Brasil Ltd., a wholly owned subsidiary, is incorporated in Brazil
  • 2003
    • Ipca Pharmaceuticals Inc., a wholly owned subsidiary, is incorporated in USA
    • Ipca (UK) Ltd., a wholly owned subsidiary, is incorporated UK
    • Listed by Forbes in Asia’s 200 Best Under A Billion
  • 2004
    • Receives Lifetime Achievement Award for 2002-03 from CHEMEXIL
    • Listed (for the second time in a row) by Forbes in Asia’s 200 Best Under A Billion
  • 2005 –  Listed (for the third time in a row) by Forbes in Asia’s 200 Best Under A Billion
  • 2006 – Enters into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the US market
  • 2007
    • Acquires full shareholding of companies in Australia and New Zealand holding Formulation Dossier registrations
    • Listed (for the fourth time) by Forbes in Asia’s 200 Best Under A Billion
  • 2008
    • Becomes the first company to launch Hydroxy Chloroquine Sulphate in Kenya after innovator brand
    • Receives the D&B - ECGC Indian Exporters Excellence Award – for being the top exporter in the large pharmaceutical sector
    • Receives approval from US FDA for Propranolol Hydrochloride Tablets
    • Receives approval from PMDA-Japan for API manufacturing plants situated at Ankleshwar and Nandesari
  • 2009 – Receives Gold Patent Award from Pharmexcil for 2008-2009 for commendable contribution in APIs
  • 2010 – Named in the list of India's Best Companies to Work For – 2010 in a survey conducted jointly by The Great Place to Work® Institute and The Economic Times
  • 2011 – Acquires 100% share capital of Onyx Research Chemicals Ltd., the holding company of Onyx Scientific Ltd. via its wholly owned UK subsidiary
  • 2012 – Receives the ECGC – D&B Indian Exporters’ Excellence Award for:
    •  Most Diversified Exporter
    •  Exporter with the Best Risk Management Practices (Second Runner-up)
  • 2013
    • Receives Environmental Award for API Plant at Indore for the fiscal year 2011-2012
    • Features 8th in the list of India's Most Admired Companies in a Fortune India survey (in collaboration with The Hay Group) for the second time
    • Two brands (Albendazole and Nemozole) make it to the No. 1 position in Russia by capturing 40% market share in the anthelmintics brand category
  • 2014
    • Acquires formulations manufacturing unit at Tarapur in Maharashtra
    • Acquires high Potency oral solid dosage Formulations manufacturing unit at Pithampur in Madhya Pradesh
  • 2015
    • Formulation brand, Zerodol, crosses the INR 200 crore mark
    • Receives Silver Award for best new introduction in the chronic segment for Kera XL, a haircare brand

 

BOARD OF DIRECTORS

  • Chairman & Managing Director: Mr. Premchand Godha
  • Joint Managing Director: Mr. Ajit Kumar Jain
  • Executive Director: Mr. Pranay Godha,  Mr. Prashant Godha
  • Non-Executive Directors: Mr. Babulal Jain,   Mr. Anand T Kusre,  Mr. Anand T Kusre,  Mr. Dev Parkash Yadava,  Dr. Ramakanta M Panda,  Dr. (Mrs) Manisha Premnath

 

 

Ipca Office Address & Contact Details:

 

CORPORATE OFFICE

Ipca Laboratories Limited

142 AB, Kandivli Industrial Estate

Kandivli (West)

Mumbai – 400 067, Maharashtra

Tel: +91 (22) 6647 4747

Fax: +91 (22) 2868 6954 / 2875

Website: http://www.ipcalabs.com/

REGISTERED OFFICE & INTERNATIONAL MARKETING

Ipca Laboratories Limited

48, Kandivli Industrial Estate
Kandivli (West)

Mumbai – 400 067, Maharashtra

Tel: 91 (22) 6647 4444

Fax: 91 (22) 2868 6613

AUSTRALIA OFFICE

Ipca Pharma (Australia) Pty. Limited

6, Morotai Avenue, Ashburton, vic 3147

Melbourne, Australia

Tel: +613 98856172

Fax: +613 98856173

USA OFFICE

Ipca Pharmaceuticals, Inc.

51, Cragwood Road, Suite No. 203, South Plainfield

New Jersey, 07080

Tel: +1 908 412 6561/ (D)908 412 6563

Fax: +1 908 412 6564

Email: jpghasit.bhatt@ipcausa.com

UK OFFICE

Ipca Laboratories (UK) Limited

Units 97-98, Silverbriar

Sunderland Enterprise Park East

Sunderland SR5 2TQ UK

Tel: +44 (0) 191 516 6 517

Fax: +44 (0) 191 516 6 526

SOUTH AFRICA OFFICE

ational Druggists (Pty.) Limited

30, Marlborough Road, Spring Field Johannesburg

2190 Gauteng, S.A.

Tel: +27 011 4345669

Fax: +27 011 4345719

CHINA OFFICE

Ipca Pharmaceuticals (Shanghai) Limited

Room 1110, 11/F Hua Tian Holiday Hotel

Office Building 469, Zhonghua Xin Road,

Zhabei District, Shanghai 200070

P. R. China

Tel: +86 21 6095 4728

KAZAKHSTAN OFFICE

Ipca Laboratories Limited

Kurmangazy Street, "48" A, Office-7, Almaty 050000

Republic of Kazakhstan

Tel: +7 727 2615141

COLOMBIA OFFICE

Ipca Laboratories Limited Sucursal Colombia

Av. 15 No. 100-69, Edificio Vangurdia 101

Oficina 401 Bogota - Colombia

Tel: +57-1-6102914 / 6102917

Email: jpgshashil.mendonsa@ipca.com

KENYA OFFICE

Ipca Laboratories Limited

East Africa Regional Office, Office No - 2A5 2nd Floor

Wing 'A', Occidental Plaza

Westlands, Nairobi, Kenya

Tel: +254 20 374 1330 / 348

Email: jpgvijayan.nair@ipca.com

MEXICO OFFICE

Ipca Pharmaceuticals Limited S.A. DE. C.V

Presa la Angostura #116, Colonia Irrigación, Delegación

Miguel Hidalgo, C.P. 11500,

Alvaro Obregon, Mexico D.F.

Tel: +52 55 53952590 / 3645, +52 55 5572642

Email: jpgshashil.mendonsa@ipca.com

NIGERIA OFFICE

Ipca Pharma Nigeria Limited

17, Osolo Way

Ajao Estate, Isolo
Lagos, Nigeria

Tel: +2341 7926460 / 4528738

Fax: +2341 4521146

Email: jpgshashil.mendonsa@ipca.com

NEW ZEALAND OFFICE

Ipca Pharma (NZ) Pty. Limited

3-A, St. Oswalds Road
Greenlane, Auckland – 1061

New Zealand

Tel: +64 2136 0880

PORTUGAL OFFICE

Ipca Produtos Farmaceuticos, Unipessoal Lda

Rua Jose Nogueira Vaz, Lote 104 – Lja Esqa

2625-099 Povoa de Santa Iria

Portugal

Tel: +351 219 531437 / 219 569745

Fax: +351 219 594073

PHILLIPINES

Ipca Laboratories Inc.

Unit - 1014, Cityland Condomonium 10, Tower -2

H.V. Dela Costa Street, Makati, Metro Manila

Philippines

Tel: +63 2812 5509

RUSSIA OFFICE

Ipca Laboratories Limited

Flat No. 235, Building 36/2, Rublovsky Shosse

Moscow 121 609

Russia

Tel: +7 495 415 43 04 / 09

SRI LANKA

Ipca Laboratories Limited

Sri Lanka Representative Office, 14-1/2

Sunethradevi Road Kohuwala, Nugegoda

Sri Lanka

Tel: +9411 5659588

Fax: +9411 2865242

UKRAINE OFFICE

Ipca Laboratories Limited

Street Patrisa Lumumba, 4/6B

Office - 1106

Kiev - 01042, Ukraine

Tel: +38044 201 02 63 / 528 76 68

Fax: +38044 201 02 62

VIETNAM OFFICE

Ipca Laboratories Limited

Century 21 Building, Block "A", Flat No. 5, Level 2

Una Van Khiem Street, District Binh Thanh, HCMC Vietnam

Tel: +84 873031833

Fax: +84 873000236

   

 

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...